Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Video
Apr 16, 2020
| Erica Klinger
COVID-19 Response: Roby Epting at Sandoz
Presentation
Apr 10, 2020
| Erica Klinger
Generics and Biosimilars Industry Supply Chain & Response to COVID-19
Fact Sheet
Mar 31, 2020
| Erica Klinger
AAM Letter to President on "Buy American" Requirements
Blog
Mar 30, 2020
| Jeff Francer
COVID-19: This Week’s Initiatives From the Generic and Biosimilars Industry
Press Release
Mar 24, 2020
| Rachel Schwartz
AAM Statement: Preserving Patient Access to Low-Cost Medicines Through COVID-19 and Beyond
Fact Sheet
Mar 20, 2020
| Erica Klinger
AAM Buy American Fact Sheet
Blog
Mar 19, 2020
| Jeff Francer
AAM’s COVID-19 Response: Helping Patients and Families Meet Their Health Care Needs
Blog
Feb 28, 2020
| Jeff Francer
AAM Interim CEO Jeff Francer on COVID-19
Blog
Feb 28, 2020
| Erica Klinger
Stories and Data: How AAM Equips Advocates in the States
Blog
Feb 27, 2020
| Erik Komendant
The First (Price) Cut Is the Steepest
Blog
Feb 25, 2020
| Sara Skubikowski
Savings by Condition: The Latest Data
Press Release
Feb 24, 2020
| Rachel Schwartz
AAM and the Biosimilars Council Applaud FDA’s Release of Enhanced Purple Book
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2024
GRx+Biosims 2023
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action